Andrew Elzinga consults on litigation and regulatory investigations arising in the life sciences and healthcare industries. Dr. Elzinga leads case teams to analyze a range of complex antitrust and competition issues, including class certification, market definition and market power, and liability. He also addresses lost profits and damages in patent infringement and breach of contract matters. Dr. Elzinga works with attorneys in all phases of the litigation process and supports experts through discovery, deposition, and trial.
Dr. Elzinga’s experience includes:
- Analyzing antitrust allegations involving reverse payments and product hopping across a number of matters, including In re HIV Antitrust Litigation
- Examining class certification issues in antitrust matters related to end-payor and direct purchaser class actions
- Evaluating allegations of market foreclosure and damages for physician-administered drugs in Fresenius Kabi USA LLC v. Par Sterile Products LLC et al.
- Assessing market definition and market power in pharmaceutical markets
- Estimating lost profits in patent infringement matters involving biologic and biosimilar drugs
- Analyzing damages, commercial success, and irreparable harm in patent infringement matters
- Evaluating competitive effects and efficiencies in the $67 billion vertical merger between health insurer Cigna and Express Scripts, a pharmacy benefit manager (PBM)
- Analyzing market definition, market power, and procompetitive benefits in Oscar Insurance Company of Florida v. Blue Cross and Blue Shield of Florida, Inc. et al.
Cornerstone Research Announces Promotions to Principal
In re HIV Antitrust Litigation
The Inflation Reduction Act Could Have Unintended Consequences
Economic Issues in Assessing Potential and Nascent Competition
Fresenius Kabi USA LLC v. Par Sterile Products LLC et al.
Expectations for Healthcare Mergers During the Pandemic
Healthcare Merger Analysis
Cigna’s Acquisition of Express Scripts